Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons
August 26th, 2021
5.4K views
We describe a method for differentiating spinal cord human induced pluripotent-derived astrocytes and neurons and their co-culture for electrophysiological recording.
Overview
This study describes a method for differentiating spinal cord human induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, facilitating their co-culture for electrophysiological recordings. The developed technique enables researchers to analyze neuronal activity influenced by astrocytes, contributing to the investigation of spinal cord diseases.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Electrophysiology
Background
- Spinal cord neurons play a critical role in neurodegenerative diseases.
- Astrocytes influence neuronal behavior and health.
- Human iPSC technology provides a relevant model for studying these interactions.
- The method aids in understanding diseases such as amyotrophic lateral sclerosis (ALS).
Purpose of Study
- To create spinal cord neuron and astrocyte models for electrophysiological analysis.
- To assess the effects of neuronal factors and astrocyte interactions.
- To aid in the study of spinal cord specific diseases.
Methods Used
- Cell culture methods to generate human iPSC-derived astrocytes and neurons.
- Neural differentiation protocols with specific media and incubation conditions.
- Co-culture techniques for simultaneous recording of neuronal activity influenced by astrocytes.
- Electrophysiological recording after establishing co-cultures over set timelines.
Main Results
- The co-culture method enables robust electrophysiological recording of neuron activity.
- Observations allow for studying cellular interactions relevant to disease mechanisms.
- Critical influences of astrocytic support on neuronal health and function were noted.
- Lay the groundwork for exploring therapeutic interventions targeting neurons and astrocytes.
Conclusions
- This method enhances the understanding of spinal cord cell interactions and their implications in disease.
- It enables a detailed investigation of cellular responses under different conditions.
- The findings support further exploration into neurodegenerative diseases and potential treatments.
Frequently Asked Questions
What are the advantages of using human iPSC-derived cells?
Human iPSC-derived cells provide a relevant model system that closely mimics human physiology and disease conditions, allowing for more accurate experimental insights.
How is the differentiation into neural progenitor cells achieved?
Differentiation involves the use of specific induction media and carefully controlled incubation conditions to promote the growth of neural progenitor cells from human iPSCs.
What types of data are obtained from this co-culture system?
Electrophysiological data is collected to analyze neuronal activity, influenced by the presence and support from co-cultured astrocytes, providing insights into cellular interactions.
How can the method be adapted for other research questions?
The co-culture method can be modified by introducing different growth factors or inhibitors to examine various pathways and interactions in neuronal health and disease.
What are the key limitations of this approach?
Limitations may include variability in differentiation efficiency and potential challenges in maintaining cell viability over extended culture periods, which can affect experimental outcomes.
Executive Industry Relevance
Regionally-specific human iPSC-derived astrocyte and neuron co-cultures, combined with multi-electrode array (MEA) electrophysiology, enable disease-relevant modeling of ALS and other neurodegenerative disorders. This platform supports predictive confidence in early discovery by capturing glia-neuron interactions and functional network maturation in a scalable, reproducible system. The approach informs target validation and de-risking at the intersection of disease biology and translational assay development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of glia-neuron interactions critical for ALS pathophysiology.
- Supports functional target validation by quantifying neuronal network maturation and activity.
- Facilitates mechanistic de-risking through regionally-specific cell identity and disease modeling.
- Provides a platform for hypothesis-driven testing of patient-derived or genetically modified cells.
Screening & Assay Development
- Delivers a validated, scalable co-culture system for quantitative MEA readouts.
- Standardizes assay conditions for reproducible measurement of spiking and bursting activity.
- Enables compound evaluation targeting neuron or astrocyte function in a human-relevant context.
- Supports platform reuse across different regional identities and disease models.
Translational & Preclinical Research
- Aligns in vitro functional outputs with disease-relevant biomarkers for ALS.
- Provides continuity from early discovery to preclinical validation using patient-derived cells.
- Enables risk-adjusted advancement decisions based on quantitative electrophysiological endpoints.
- Facilitates translational biomarker development by linking cellular phenotypes to functional readouts.
Pipeline & Workflow Integration
This co-culture MEA platform bridges early discovery, target validation, and preclinical research by enabling functional assessment of human neural networks under disease-relevant conditions.
- Discovery Biology: Supports hypothesis testing of glia-neuron mechanisms and pathway involvement in ALS.
- Screening: Provides reproducible, quantitative electrophysiological outputs for compound and genetic perturbation studies.
- Analytics: Delivers network-level activity metrics (spiking, bursting) for robust condition comparison.
- Translational Research: Connects in vitro functional phenotypes to disease biomarkers and patient-derived models.
- Enterprise Reuse: Adaptable to other CNS regions and neurodegenerative disease models for portfolio-wide application.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in ALS modeling.
- Operational Value: Standardizes co-culture and MEA workflows for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and capital allocation by providing quantitative, disease-relevant endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of neurodegenerative disease programs.
Implementation Considerations
- Requires expertise in human iPSC culture, neural differentiation, and MEA operation.
- Demands access to specialized instrumentation for electrophysiological recording and data analysis.
- Necessitates rigorous cross-team standardization of differentiation and co-culture protocols.
- Adaptable to various regional identities and disease models with protocol modifications.
- Technical sensitivity during early differentiation stages may limit throughput and troubleshooting flexibility.
Biopharma FAQs
Why does null hypothesis testing matter for MEA-based ALS target validation?
Null hypothesis testing in MEA assays enables objective evaluation of whether observed changes in neuronal network activity are statistically significant, supporting robust target validation in ALS models. This approach reduces bias and increases confidence in mechanistic findings relevant to disease biology and therapeutic intervention.
How does independent variable isolation fit the co-culture electrophysiology workflow?
Isolating variables such as astrocyte or neuron subtype, or compound exposure, allows teams to attribute functional changes in network activity to specific experimental factors. This precision is essential for dissecting glia-neuron interactions and optimizing assay conditions for discovery-stage decision making.
What do quantitative MEA-dependent variable measurements enable in ALS modeling?
Quantitative MEA outputs, including spiking and bursting rates, provide actionable metrics for comparing disease and control conditions, assessing compound effects, and tracking network maturation. These measurements underpin data-driven advancement and triage of ALS therapeutic hypotheses.
Why are replication requirements critical for cross-functional ALS research teams?
Replication ensures that observed electrophysiological phenotypes are robust and reproducible across experiments, cell lines, and operators. This reliability is vital for cross-functional collaboration, enabling consistent data interpretation and portfolio-wide assay adoption.
What statistical analysis capabilities are required before implementing MEA-based ALS assays?
Teams must establish statistical workflows for analyzing network activity metrics, including baseline normalization, significance testing, and variance assessment. These capabilities are essential for rigorous data interpretation and informed decision making in ALS-focused R&D.
Chapters in this video
0:04
Introduction
0:48
Maintaining Non-Confluent Human Induced Pluripotent Stem Cells
2:58
Diffrentiation of NPC into Motor Neuron
3:46
Co-Culturing Motor Neurons and Astrocytes in Multi-Electrode Array Plates
7:42
Multi-Electrode Array Recording
8:16
Pharmacological Assays on Multi-Electrode Array
9:01
Results: Human Pluripotent Stem Cell-Derived Motor Neurons and Astrocytes
11:09
Conclusion
